Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Regenerative Medical Technology (RMTG) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Regenerative Medical Technology's Cash & Equivalents rose 4175.71% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 4175.71%. This contributed to the annual value of $1.2 million for FY2024, which is 11974.21% up from last year.
  • According to the latest figures from Q3 2025, Regenerative Medical Technology's Cash & Equivalents is $1.2 million, which was up 4175.71% from $1.6 million recorded in Q2 2025.
  • Regenerative Medical Technology's Cash & Equivalents' 5-year high stood at $10.7 million during Q3 2021, with a 5-year trough of $530540.0 in Q4 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $1.2 million (2023), whereas its average is $2.3 million.
  • As far as peak fluctuations go, Regenerative Medical Technology's Cash & Equivalents skyrocketed by 9060242.03% in 2021, and later plummeted by 8350.59% in 2022.
  • Over the past 5 years, Regenerative Medical Technology's Cash & Equivalents (Quarter) stood at $3.0 million in 2021, then plummeted by 44.77% to $1.6 million in 2022, then crashed by 67.75% to $530540.0 in 2023, then surged by 119.74% to $1.2 million in 2024, then rose by 1.7% to $1.2 million in 2025.
  • Its Cash & Equivalents was $1.2 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.2 million in Q1 2025.